Setrobuvir [CAS 1071517-39-9]

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition[1][2].

[1071517-39-9]

C25H25FN4O6S2

560.62

CS(=O)(NC1=CC=C(C2=C1)N=C(C3=C(O)[C@]4([H])[C@@](C5)([H])CC[C@@]5([H])[C@]4([H])N(CC6=CC=C(F)C=C6)C3=O)NS2(=O)=O)=O

DNA/RNA Synthesis; HCV; SARS-CoV

10 mM in DMSO

Room temperature